Page 1

PAVmed PAVmed Provides Business Update and First Quarter 2021 Financial Results May 17 , 2021 Conference call to be held today at 4:30 PM EDT NEW YORK , May 17 , 2021 ( GLOBE NEWSWIRE ) -- PAVmed Inc. ( Nasdaq : PAVM , PAVMZ ) ( the " Company " or " PAVmeď ” ) , a highly differentiated , multi - product , commercial stage medical device company , today provided a business update for the Company and its major subsidiary , Lucid Diagnostics Inc. ( " Lucid " ) , and discussed financial results for the three months ended March 31 , 2021 . " I am delighted with the solid momentum we have experienced during the first quarter of 2021 and in subsequent weeks , " said Lishan Aklog , M.D. , PAVmed's Chairman and Chief Executive Officer . " We continue to expand our commercial infrastructure and drive EsoGuard commercialization , while advancing products across our portfolio . We have strengthened our balance sheet , with $ 49 million in cash as of March 31 , 2021 , sufficient to fund our current operations into 2023 , and no debt . We also continue to take important steps to support an expanded strategic vision to enhance shareholder value , including seeking to take Lucid public , adding deep commercial experience to our Board of Directors , and exploring exciting new opportunities to partner on groundbreaking innovations . " Conference Call and Webcast A conference call and webcast for today's business update and first quarter 2021 financial results will take place at 4:30 PM EDT . To access the conference call , listeners should dial ( 877 ) 407-3982 toll - free in the U.S. or ( 201 ) 493-6780 , and ask to join the " PAVmed , Inc. Business Update Conference Call " . The conference call will be available live via webcast and for replay at the investor relations section of the Company's website at www.pavmed.com . Following the conclusion of the conference call , a replay will be available for one week and can be accessed by dialing ( 844 ) 512-2921 toll - free in the U.S. or ( 412 ) 317-6671 , followed by the PIN number : 13719121 . Business Update Highlights • Lucid significantly expanded its full - time commercial team to accelerate execution of a pillar of its growth strategy , commercializing its EsoGuard® Esophageal DNA Test across multiple channels . Hired four industry veterans into senior leadership roles - Director of Sales , VP of Market Access & Reimbursement , National Sales Training Manager and Strategic Accounts Manager . • EsoGuard testing accelerated as pandemic - related healthcare facility limitations eased . Lucid processed 78 EsoGuard tests in Q1 and 96 in the first half of Q2 . Clinicians have been trained , and EsoCheck® Cell Collection Devices and EsoGuard Specimen Kits are in stock , at approximately 180 U.S. accounts . Lucid began to submit EsoGuard